Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

6 Months Ended

Jan. 31, 2017

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended January 31, 2017	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	18,837			—			—			—		$	18,837
Product revenues		—		$	6,983			—			—			6,983
Royalty and license fee income		—			440			—			—			440
		18,837			7,423			—			—			26,260
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services		11,052			—			—			—			11,052
Cost of product revenues		—			3,520			—			—			3,520
Research and development		—			516		$	(33	)		—			483
Selling, general and administrative		5,897			2,905			—		$	2,363			11,165
Provision for uncollectible accounts receivable		594			85			—			—			679
Legal fee expense		49			16			—			305			370
Total operating costs, expenses and legal settlements, net		17,592			7,042			(33	)		2,668			27,269

Operating income (loss)		1,245			381			33			(2,668	)		(1,009	)

Other income (expense):
Interest		(28	)		12			—			95			79
Other		17			—			—			7			24
Foreign exchange loss		—			(94	)		—			—			(94	)
Income (loss) before income taxes	$	1,234		$	299		$	33		$	(2,566	)	$	(1,000	)

Depreciation and amortization included above	$	394		$	501		$	—		$	20		$	915

Share-based compensation included in above:
Cost of clinical laboratory services	$	1			—			—			—		$	1
Selling, general and administrative		23		$	15			—		$	202			240
Total	$	24		$	15		$	—		$	202		$	241

Capital expenditures	$	175		$	—		$	—		$	—		$	175

Three months ended January 31, 2016	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	17,523			—			—			—		$	17,523
Product revenues		—		$	6,578			—			—			6,578
Royalty and license fee income		—			459			—			—			459
		17,523			7,037			—			—			24,560
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services		10,535			—			—			—			10,535
Cost of product revenues		—			3,206			—			—			3,206
Research and development		—			661		$	200			—			861
Selling, general and administrative		5,649			2,773			—		$	2,858			11,280
Provision for uncollectible accounts receivable		467			(8	)		—			—			459
Legal fee expense		57			5			—			2,349			2,411
Legal settlements, net		1,500			(13,150	)		—			—			(11,650	)
Total operating costs, expenses and legal settlements, net		18,208			(6,513	)		200			5,207			17,102

Operating income (loss)		(685	)		13,550			(200	)		(5,207	)		7,458

Other income (expense)
Interest		(23	)		17			—			(36	)		(42	)
Other		(1	)		—			—			12			11
Foreign exchange loss		—			(388	)		—			—			(388	)
Income (loss) before income taxes	$	(709	)	$	13,179		$	(200	)	$	(5,231	)	$	7,039

Depreciation and amortization included above	$	411		$	524		$	—		$	17		$	952

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Selling, general and administrative		9		$	5			—		$	94			108
Total	$	11		$	5		$	—		$	94		$	110

Capital expenditures	$	354		$	84		$	—		$	—		$	438

Six months ended January 31, 2017	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	37,395			—			—			—		$	37,395
Product revenues		—		$	14,409			—			—			14,409
Royalty and license fee income		—			740			—			—			740
		37,395			15,149			—			—			52,544
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services		21,948			—			—			—			21,948
Cost of product revenues		—			6,829			—			—			6,829
Research and development		—			1,143		$	162			—			1,305
Selling, general and administrative		11,849			5,851			—		$	4,939			22,639
Provision for uncollectible accounts receivable		1,260			88			—			—			1,348
Legal fee expense		101			28			—			613			742
Total operating costs, expenses and legal settlements, net		35,158			13,939			162			5,552			54,811

Operating income (loss)		2,237			1,210			(162	)		(5,552	)		(2,267	)

Other income (expense):
Interest		(57	)		22			—			160			125
Other		119			—			—			24			143
Foreign exchange loss		—			(455	)		—			—			(455	)
Income (loss) before income taxes	$	2,299		$	777		$	(162	)	$	(5,368	)	$	(2,454	)

Depreciation and amortization included above	$	795		$	1,009		$	—		$	38		$	1,842

Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Selling, general and administrative		40		$	26			—		$	323			389
Total	$	43		$	26		$	—		$	323		$	392

Capital expenditures	$	587		$	102		$	—		$	—		$	689

Six months ended January 31, 2016	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	34,613			—			—			—		$	34,613
Product revenues		—		$	14,265			—			—			14,265
Royalty and license fee income		—			859			—			—			859
		34,613			15,124			—			—			49,737
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services		20,867			—			—			—			20,867
Cost of product revenues		—			6,817			—			—			6,817
Research and development		—			1,328		$	400			—			1,728
Selling, general and administrative		10,935			5,832			—		$	4,738			21,505
Provision for uncollectible accounts receivable		1,175			(12	)		—			—			1,163
Legal fee expense		66			(17	)		—			3,963			4,012
Legal settlements, net		1,500			(19,950	)		—			—			(18,450	)
Total operating costs, expenses and legal settlements, net		34,543			(6,002	)		400			8,701			37,642

Operating income (loss)		70			21,126			(400	)		(8,701	)		12,095

Other income (expense)
Interest		(42	)		31			—			(71	)		(82	)
Other		3			39			—			23			65
Foreign exchange loss		—			(518	)		—			—			(518	)
Income (loss) before income taxes	$	31		$	20,678		$	(400	)	$	(8,749	)	$	11,560

Depreciation and amortization included above	$	808		$	1,054		$	—		$	40		$	1,902

Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Selling, general and administrative		19		$	10			—		$	189			218
Total	$	22		$	10		$	—		$	189		$	221

Capital expenditures	$	791		$	152		$	—		$	—		$	943